US-based Gilead Sciences has reported topline results from a Phase III clinical trial (GS-US-337-0113) of the investigational once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90mg and nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400mg to treat Japanese patients with genotype 1 chronic hepatitis C virus (HCV) infection.

Among patients receiving 12 weeks of LDV/SOF without RBV, 100% of treatment-naive and 100% of treatment-experienced patients achieved a sustained virologic response 12 weeks after completing therapy (SVR12).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

In patients receiving LDV/SOF plus RBV, 96% of treatment-naive and 100% of treatment-experienced patients achieved SVR12.

The company said that across all arms of the trial, patients with cirrhosis achieved a 99% SVR12 and those who achieve SVR12 are considered cured of HCV infection.

"These results suggest that a once-daily LDV/SOF tablet has the potential to be an efficacious and well-tolerated regimen for many HCV patients in Japan."

The trial also met its primary endpoint of superiority compared with a predefined historical SVR12 rate.

See Also:

Gilead executive vice-president of research and development and chief scientific officer Norbert Bischofberger said: "These results suggest that a once-daily LDV/SOF tablet has the potential to be an efficacious and well-tolerated regimen for many HCV patients in Japan."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In Japan, Genotype 1 is the most common strain of HCV, accounting for around 70% of the more than one million people chronically infected with the disease.

In the trial, 341 patients with genotype 1 HCV infection were randomised (1:1) to receive 12 weeks of all-oral therapy with LDV/SOF, with or without RBV.

Out of these, 166 patients were treatment-naive, 175 were treatment-experienced and 76 had compensated cirrhosis.

Based on these data, the company intends to submit a New Drug Application for the LDV/SOF fixed-dose combination with the Japanese Pharmaceutical and Medical Devices Agency (PMDA) by the end of 2014.

The product is currently under regulatory review in the US and EU.